Analysis of Serum Lipids and Lipoprotein Electrophoresis Fractions in Hypertensive Patients

  • Kim, Chong-Ho (Department of Clinical Laboratory Science, Wonkwang Health Science University)
  • Received : 2011.06.03
  • Accepted : 2011.06.18
  • Published : 2011.06.30

Abstract

We analyzed the concentration of serum total cholesterol (TC), high density lipoprotein cholesterol (HDLC), low density lipoprotein cholesterol (LDLC), triglyceride (TG) and the serum lipoprotein electrophoresis fractions in hypertensive patients (hypertension group, n=182). The average concentration of lipids and lipoprotein fractions in the hypertension group was compared to that of the normal group. The average concentrations of serum TC, LDLC and TG in the hypertension group were significantly higher than those of the normal group (3.3%, 11% and 70%, respectively) (P<0.05). But HDLC was nonsignificantly lower (2%) (P<0.05). In the hypertension group, the percentages of patients who had an abnormally high level of total cholesterol, HDLC, LDLC and TG were 12.1%, 8.2%, 24.2% and 44.5%, respectively. The average of ${\beta}$-lipoprotein (27.5%) and pre ${\beta}$-lipoprotein (12.6%) were significantly higher, whereas ${\alpha}$-lipoprotein (15.2%) was significantly lower in the hypertension group than in the normal group (P<0.05). The percentages of patients who had an abnormally high level of very low density lipoprotein (pre ${\beta}$-LP), LDLC (${\beta}$-LP) and chylomicron were 31.3%, 17.0% and 12.6%, respectively. This study suggests that an increasing of total cholesterol, LDLC and TG, pre ${\beta}$-LP, ${\beta}$-LP and chylomicron are associated with a risk factor for hypertension.

Keywords

References

  1. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998. 81: 7B-12B. https://doi.org/10.1016/S0002-9149(98)00031-9
  2. Chobanian AV, Bakris GL, Black HR. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA. 2003. 289: 2560-2572. https://doi.org/10.1001/jama.289.19.2560
  3. Cornoni HJ, LaCroix AZ, Havlik RJ. Race and sex differentials in the impact of hypertension in the United States. The National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Intern Med. 1989. 149: 780-788. https://doi.org/10.1001/archinte.1989.00390040022005
  4. Dahlen GH, Stenlund H. Lp (a) lipoprotein is a major risk factor for cardiovascular disease. Pathogenic mechanisms and clinical significance. Clin Genet. 1997. 52: 272-280.
  5. Falco C, Estelles A, Dalmau J, Espana F, Aznar J. Influence of lipoprotein (a) levels and isoforms on fibrinolylic activity, study in families with high lipoprotein(a) Levels. Thromb-Haemost. 1998. 79: 818-823.
  6. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972. 18: 499-502.
  7. Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 2002. 106: 2137-2142. https://doi.org/10.1161/01.CIR.0000035280.64322.31
  8. Gotto J, Antonio M. Evolving concepts of dyslipidemia, atherosclerosis, and cardiovascular disease. J Am Coll Cardiol. 2005. 46: 1219-1224. https://doi.org/10.1016/j.jacc.2005.06.059
  9. Groop L, Orho MM. The dysmetabolic syndrome. J Intern Med. 2001. 250: 105-120. https://doi.org/10.1046/j.1365-2796.2001.00864.x
  10. Haffner SM, Ferrannini E, Hazuda HP, Stern MP. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 1992. 20: 38-45. https://doi.org/10.1161/01.HYP.20.1.38
  11. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Metabolic precursors of hypertension. The San Antonio Heart Study. Arch Intern Med. 1996. 156: 1994-2001. https://doi.org/10.1001/archinte.1996.00440160106013
  12. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in arteriosclerosis. Nature 1989. 39: 303-315.
  13. Halperin RO, Sesso HD, Ma J, Buring JE, Stampfer MJ, Michael Gaziano J. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006. 47: 45-50. https://doi.org/10.1161/01.HYP.0000196306.42418.0e
  14. Hunt SC, Stephenson SH, Hopkins PN, Williams RR. Predictors of an increased risk of future hypertension in Utah: ascreeninganalysis. Hypertension 1991. 17: 969-976. https://doi.org/10.1161/01.HYP.17.6.969
  15. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006. 113: 1888-1904. https://doi.org/10.1161/CIRCULATIONAHA.105.563213
  16. Labeur C, De Bacques D, De Backer G, Vinke J, Muyldermans L, Vandekerckhove Y. Plasma lipoprotein (a) values and severity of coronary Artery Disease in a Large population of patients undergoing coronary angiography. Clin Chem. 1992. 38: 2261-2266.
  17. Laaksonen DE, Niskanen L, Lakka HM, Lakka TA, Uusitupa M. Epidemiology and treatment of the metabolic syndrome. Ann Med. 2004. 36: 332-346. https://doi.org/10.1080/07853890410031849
  18. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM. DNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987. 300: 132-137.
  19. Naito HK, Wada M, Erhart A. Polyacrylamide gel disc electrophoresis as a screening procedure for serum lipoprotein abnormalities. Clin Chem. 1973. 19: 228-234.
  20. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003. 139: 761-776. https://doi.org/10.7326/0003-4819-139-9-200311040-00011
  21. Pyrorala KG, De Backer I, Graham P, Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the task force of the European Societyof Cardiology, Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994. 110: 121-161. https://doi.org/10.1016/0021-9150(94)90200-3
  22. Scott MG, Diane B, Luther TC, Richard SC, Margo AD, Wm JH, Donald BH, Russell VL, Patrick M, James MM, Richard CP, Neil JS, Linda VH. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001. 285: 2486-2497. https://doi.org/10.1001/jama.285.19.2486
  23. Sesso HD, Buring JE, Chown MJ, Ridker PM, Gaziano JM. A prospective study of plasma lipid levels and hypertension in women. Arch Intern Med. 2005. 165: 2420-2427. https://doi.org/10.1001/archinte.165.20.2420
  24. Skarfors ET, Lithell HO, Selinus I. Risk factors for the development of hypertension: the San Antonio Heart Study. Arch Intern Med.1996. 156: 1994-2000. https://doi.org/10.1001/archinte.1996.00440160106013
  25. Skarfors ET, Lithell HO, Selinus I. Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. J Hypertens. 1991. 9: 217-223. https://doi.org/10.1097/00004872-199103000-00004
  26. Tremblay AJ, Morrissette H, Gagne JM, Bergeron J, Gagne C, Couture P. Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population. Clin Biochem. 2004. 37: 785-790. https://doi.org/10.1016/j.clinbiochem.2004.03.008
  27. Wilson PW, Zech LA, Gregg RE, Schaefer EJ, Hoeg JM, Sprecher DL, Brewer HB Jr. Estimation of VLDL cholesterol in hyperlipidemia. Clin Chim Acta. 1985. 151: 285-291. https://doi.org/10.1016/0009-8981(85)90091-9
  28. Wilson PW, Zech LA, Gregg RE, Schaefer EJ, Hoeg JM, Sprecher DL, Brewer HB Jr. Estimation of formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification cholesterol from data on triglyceride concentration in plasma. Clin Chem. 1981. 27: 2008-2010.